# **ORGANOMETALLICS**

### Ligand Rearrangement Leads to Tetrahydrothiophene-Functionalized N,S-Heterocyclic Carbene Palladium(II) Complexes

Andrew M. Romine, Matthew J. Demer, Milan Gembicky, Arnold L. Rheingold, and Keary M. Engle\*

Cite This: https://doi.org/10.1021/acs.organomet.1c00041





clic carbene palladium(II) complexes are synthesized through an unexpected rearrangement that proceeds with palladium(II) trifluoroacetate but not with palladium(II) acetate, palladium(II) bromide, or palladium(II) chloride. A series of these complexes were isolated and characterized by X-ray crystallography. The mechanism of formation of these [3.2.1]palladabicycles was



explored, and the catalytic capabilities of these complexes were demonstrated in representative C-C coupling reactions.

#### INTRODUCTION

The past few decades have witnessed a surge of interest in carbenes as spectator ligands in transition-metal catalysis.<sup>1</sup> An increasingly vast collection of ligands, including N-heterocylic carbenes (NHCs),<sup>2</sup> cyclic (alkyl)- and (aryl)(amino)carbenes (CAACs),<sup>3</sup> and abnormal NHCs (*a*NHCs),<sup>4</sup> have been developed that collectively grant access to diverse steric and electronic properties useful in catalyst development (Scheme 1A). While much of the research on NHC–metal complexes



has focused on those in which the metal is coordinated to the C atom between two nitrogen atoms in an imidazole-based framework, <sup>1d,2i</sup> interest in similar carbenes,<sup>5</sup> such as those where one N atom is replaced with an O (oxazole), P (phosphazole), or S atom (thiazole) has led to the naming system N,X-heterocyclic carbenes (X = O, P, S, etc.) or NXHC (Scheme 1B).<sup>6</sup> NXHC-metal complexes have been extensively explored,<sup>7</sup> with a number of studies being focused specifically on NSHC-metal complexes.<sup>6</sup>

Polydentate ligands containing either multiple tethered NHCs or an NHC and an additional pendant functional group, such as an aminophosphine,<sup>8</sup> an ester,<sup>9</sup> or others,<sup>10</sup> have also been synthetically explored. Notably, a number of palladium complexes bearing sulfur-containing NHCs have been characterized (Scheme 1C)<sup>11</sup> and shown to catalyze various reactions, such as Suzuki–Miyaura couplings,<sup>12</sup> Mizoroki-Heck reactions,<sup>13</sup> asymmetric allylic alkylations,<sup>14</sup> hydroaminations,<sup>15</sup> direct arylations,<sup>15b,16</sup> Sonogashira couplings,<sup>17</sup> and nitrile-amide interconversions.<sup>17</sup> In catalysis, metal-bound thioethers are hemilabile ligands that exhibit reversible binding to the metal center when they are incorporated in a polydentate ligand framework that contains one or multiple NHCs; this property can be useful in ligand design, for example in stabilizing resting states while still allowing dissociation to open a coordination site for the association of reactants.<sup>11d,15b,18</sup>

Special Issue: Organometallic Solutions to Challenges in Cross-Coupling

Received: January 23, 2021



#### RESULTS AND DISCUSSION

During the course of a previous study,<sup>19</sup> a mixture of 2-(but-3en-1-ylthio)benzo[d]thiazole (1a) and palladium(II) trifluoroacetate (Pd(TFA)<sub>2</sub>) was stirred at 45 °C in 1,2-dichloroethane (1,2-DCE) for 12 h in an attempt to isolate a palladium species bound to both the benzothiazole directing group and the pendant alkene. After vapor diffusion of diethyl ether into the solution, a large number of yellow crystals formed. X-ray analysis revealed these crystals to be composed of an unexpected dimeric Pd<sub>2</sub>(NSHC)<sub>2</sub>(TFA)<sub>4</sub> complex containing the C,S-bidentate bridging NSHC ligand 3-(tetrahydrothiophen-3-yl)benzo[d]thiazol-3-ium-2-ide (Figure 1). This prod-



Figure 1. Molecular structure of  $(\pm)$ -2a showing 50% probability ellipsoids. Hydrogen atoms and (CO)CF<sub>3</sub> groups from trifluoroacetate ligands are omitted for clarity. Selected bond lengths (Å) and bond angles (deg): Pd1–Pd1′ 3.2086(5), Pd1–S1 2.2581(10), N1– C1 1.482(5), N1–C5 1.332(5), N1–C11 1.407(5), S2–C5 1.711(4), S2–C10 1.736(4), S1–Pd1–C5 94.21(11), C5–Pd1–O3 90.14(13), O3–Pd1–O1 83.25(11), O1–Pd1–S1 92.48(8), C5–Pd1–Pd1′ 91.49(10).

uct,  $(\pm)$ -2a, was isolated in 82% yield, and its structure was further confirmed by <sup>1</sup>H NMR, <sup>13</sup>C NMR, and high-resolution mass spectrometry (HRMS). As of yet, a palladium complex with this type of bidentate ligand based on an NSHC with a pendant thioether has not been reported, to the best of our knowledge. Notably, when other palladium sources were used, PdBr<sub>2</sub>, PdCl<sub>2</sub>, and Pd(OAc)<sub>2</sub>, this product was not observed, suggesting that trifluoroacetate (TFA) ligands are uniquely suited for the formation of the NSHC complex (Table 1). This may be attributed to the highly electrophilic nature of the Pd center in Pd(TFA)<sub>2</sub>, which may promote key steps in the rearrangement process (*vide infra*).

This complex was of interest from both a structural and a mechanistic perspective. First, the formation of a bridged [3.2.1]palladabicycle containing a five-membered tetrahydro-thiophene ring is a unique structure combining both an NSHC and a pendant bridging cyclic thioether. Second, the significant rearrangement of the starting material, which involves the breaking of a C(benzothiazole)–S(thioether) bond and the formation of C–S and C–N bonds, requires an unusual mechanism. Furthermore, due to the previously demonstrated synthetic utility of this benzothiazole thioether directing group, <sup>19</sup> a greater understanding of this mechanism could lead to further applications in reaction development.

Finding this complex and its formation interesting, we sought to synthesize and characterize several similar compounds to understand the generality and limitations of this process (Scheme 2). (S)-2-(Pent-4-en-2-ylthio)benzo[d]-thiazole ((S)-1b), which was added in a 2:1 ratio relative to Pd(TFA)<sub>2</sub>, successfully provided product **2b** (70% yield)

Table 1. Synthesis of Bidentate NSHC  $Pd(TFA)_2$ Complexes<sup>*a*</sup>



<sup>*a*</sup>Isolated yields calculated as percentage of total possible product. <sup>*b*</sup>None isolated. <sup>*c*</sup>Observed only by <sup>1</sup>H NMR as part of a complex mixture of unassignable compounds.

## Scheme 2. Scope and Limitations of Ligand Rearrangement<sup>a</sup>



<sup>*a*</sup>Isolated yields calculated as percentage of total possible dimer. <sup>*b*</sup>Product from (S)-2-(pent-4-en-2-ylthio)benzo[*d*]thiazole. <sup>*c*</sup>*d.r.* = Diastereomeric ratio. <sup>*d*</sup>A diastereomeric ratio of 3.3:1 was seen for the racemic product, due likely to solubility differences during crystallization. <sup>*e*</sup>Reaction conditions: Pd(TFA)<sub>2</sub> (1 equiv), benzo[*d*]thiazole thioether (2 equiv), 1,2-DCE, 45 °C, 12 h, air.

(Scheme 2A), isolated as a mixture of diastereomers (dr = 1.4:1, as determined by <sup>1</sup>H NMR of the bulk solid). The <sup>1</sup>H NMR spectrum of this mixture shows that only two major species are present in solution, suggesting that this series of palladium complexes, while being Pd–Pd dimers in the solid state, are monomeric in solution, since three diastereomeric species would be expected in the case of dimers. Furthermore, the Pd–Pd bond lengths of all the dimers in crystal form are

above 3.2 Å, suggesting semicoordination that would not persist in the presence of solvent (see Table S56 in the Supporting Information). From this sample of **2b**, selective crystallization of the major *S*,*S*;*S*,*S* diastereomer allowed for further characterization by X-ray crystallography.<sup>20</sup> These findings suggest that the stereochemistry at the carbon–sulfur bond of the thioether in the starting material is maintained during the rearrangement, with the diastereoselectivity established in the bond-forming step between C1 (the carbon  $\gamma$  to the sulfur of the thioether in the starting material) and N1 with the major diastereomer favored due to attenuated steric interactions between the methyl group and palladium (Figure 2).



**Figure 2.** Two diastereomers formed in a 1.36:1 ratio, respectively, from the reaction of (S)-1b when the bulk solid was analyzed by <sup>1</sup>H NMR. Legend: (a) major and minor diastereomers observed, respectively, and identified by <sup>1</sup>H NMR and NOESY.

Next, (E)-2-(hex-3-en-1-ylthio)benzo[d]thiazole ((E)-1c), which was added in a 2:1 ratio relative to Pd(TFA)<sub>2</sub>, successfully provided complex  $(\pm)$ -2c (74% yield) (Scheme 2A). Analysis of the bulk solid by <sup>1</sup>H NMR showed that this reaction yielded a single diastereomer, and X-ray analysis of a single crystal confirmed this to be the Pd(TFA)<sub>2</sub> complex with the bidentate *trans*-3-(2-ethyltetrahydrothiophen-3-yl)-benzo-[d]thiazole-3-ium-2-ide ligand. Notably, (Z)-2-(hex-3-en-1ylthio)benzo[d]thiazole ((Z)-1c) does not provide any product for reasons that are not immediately obvious (Scheme 3). Additionally, (E)-5-chloro-2-(hex-3-en-1-ylthio)benzo[d]-





<sup>*a*</sup>Isolated yields calculated as percentage of total possible dimer. <sup>*b*</sup>Reaction conditions:  $Pd(TFA)_2$  (1 equiv), (*E*)-2-(hex-3-en-1-ylthio)benzo[*d*]thiazole (2 equiv), 1,2-DCE, 45 °C, 12 h, air. <sup>*c*</sup>Reaction conditions:  $Pd(TFA)_2$  (1 equiv), (*Z*)-2-(hex-3-en-1-ylthio)benzo[*d*]thiazole (2 equiv), 1,2-DCE, 45 °C, 12 h, air. <sup>*d*</sup>No reaction.

thiazole (1d) was also subjected to the same conditions, and complex ( $\pm$ )-2d was isolated (72% yield) (Scheme 2A). No analogous complexes were observed in attempts to use S-substituted benzo[d]thiazoles bearing internal or terminal alkynyl groups, longer or shorter tethers to the alkene, or 1,1-disubstituted terminal alkenes (Scheme 2B).

In order to gain insight into the rearrangement mechanism, we revisited the results in Table 1 to more rigorously characterize the coordination mode of the substrates in nonrearranged complexes containing other counterions. Notably, trans-PdBr<sub>2</sub>(1a)<sub>2</sub> (complex 3a) contains two molecules of the starting material coordinated through nitrogen (Figure 3). The analogous product 3b was also



Figure 3. Molecular structure of 3a showing 50% probability ellipsoids; hydrogen atoms not on alkene are omitted for clarity. Selected bond lengths [Å] and bond angles [deg]: Pd1-N1 2.017(4), N1-C5 1.311(7), N1-C11 1.405(7), S2-C5 1.738(6), S2-C10 1.741(6), N1-Pd1-Br1 88.81(13), N1-Pd1-Br2 90.61(13), N1'-Pd1-Br1 88.90(13), N1'-Pd1-Br2 91.86(13).

observed with  $PdCl_2$  (see Table 1 and Figure S11 in the Supporting Information). Under the same conditions, treating  $Pd(TFA)_2$  with 2-((2-methylbutyl)thio)benzo[d]thiazole (1e), which contains no alkene, provides the corresponding structure, 4 (Scheme 4). Of note, no evidence of palladium



C5(benzothiazole)-S1(thioether) insertion was observed, which suggests that C5(benzothiazole)-S1(thioether) oxidative addition occurs after cyclization onto the alkene. Next, we tested whether other transition metals can trigger this cyclization. To this end, 1a was treated with numerous commercially available salts, including those derived from nickel, copper, platinum, iron, ruthenium, and silver. From these experiments, we obtained a novel silver complex from the treatment of 1a (2 equiv) with silver(I) trifluoromethanesulfonate (AgOTf), which provided complex 5 (Figure 4). In the solid-state structure, Ag(I) is simultaneously bound to the thioether, the corresponding alkene, and the nitrogen of the benzothiazole group in a bimetallic dimer form, establishing that late transition metals can indeed coordinate to the alkene moiety in the presence of a benzothiazole group. Finally, consistent with a recent literature report,<sup>21</sup> we found that the treatment of 1a with an iodine source leads the substrate to



Figure 4. Isolated compounds with relevance to the proposed mechanisms.

undergo iodocyclization through nitrogen to give compound **6** (Figure 4).

On the basis of these initial results, several possible mechanisms of formation can be envisioned. Herein we describe two plausible pathways. In both proposals, we suggest that the Pd(TFA)<sub>2</sub> first coordinates to the starting material through the benzothiazole nitrogen and the alkene, as was previously computationally determined for the same starting material in an oxidative-Heck reaction with Pd(OAc)<sub>2</sub>.<sup>19</sup> While in principle this coordination could alternatively proceed through the thioether, as is seen in complex 5, or through a manner akin to that in complexes 3a, 3b, and 4, in which the Pd coordinates only to the benzo [d] thiazole nitrogen and not the alkene, the time course data suggest that an N1-bound Pd(II) species coordinated to the alkene is the major species in solution (vide infra). After substrate coordination, the first mechanistic proposal involves a cyclization via anti-aminopalladation, with the benzothiazole nitrogen acting as the nucleophile, similar to the known cyclization induced by iodine. This cyclization step most likely requires a highly electrophilic Pd, which explains the unique reactivity observed with Pd(TFA)<sub>2</sub> over Pd(OAc)<sub>2</sub>, PdBr<sub>2</sub>, and PdCl<sub>2</sub>. This could then be followed by intramolecular oxidative addition into the now weakened C5(benzothiazole)-S1(thioether) bond.<sup>22</sup> Following this, a  $C2(sp^3)$ -S1 S<sub>N</sub>2-type reductive elimination would need to occur in a stereoinvertive fashion, as has been observed previously in  $C(sp^3)$ -heteroatom reductive elimination from Pd(IV) centers.<sup>23</sup> This inversion would provide the observed final product upon S1 coordination and complex dimerization (Scheme 5A). Alternatively, a cyclization could occur first through a syn-aminopalladation that, when it is followed by oxidative addition into the C5(benzothiazole)-S1(thioether) bond and stereoretentive  $C2(sp^3)$ -S1 reductive elimination, would lead to the observed product upon thioether coordination and dimerization (Scheme 5B).

To further probe the viability of the proposed mechanisms, we monitored the reaction progress over time with two model substrates, **1a** and **1c**, at 45 °C in air in CDCl<sub>3</sub> by setting up a series of parallel trials and halting them at predetermined time points; we then assayed the solution (CDCl<sub>3</sub>) and precipitate (DMSO- $d_6$ ). In both reaction sets, a new downfield peak was observed at 9.31 ppm in CDCl<sub>3</sub> upon mixing of **1a** or **1c** with Pd(TFA)<sub>2</sub>. On the basis of shift, integration, and data from the analogous compounds **3a**, **3b**, and **4**, this peak was assigned to the N-bound Pd(II) species. This species was short-lived for the reaction with terminal alkene **1a** (Figure 5) but was persistent in the reaction with the internal alkene **1c**, suggesting that the initial cyclization is much faster for the terminal alkene. In the time-course experiment with **1c**, a downfield shift by 0.10 ppm of the alkene protons is observed,

#### Scheme 5. Plausible Mechanisms of Formation







and the new <sup>1</sup>H resonances integrate in a 1:1:1 ratio with the aryl proton peak at 9.31 ppm, suggesting the formation of a stable intermediate with palladium coordinated to the alkene, such as is seen with silver in complex 5, and to the benzothiazole nitrogen (and not the thioether). Furthermore, at 1–3 h, novel peaks at 5.88 and 6.51 ppm for the reaction with 1a in CDCl<sub>3</sub> and DMSO- $d_6$ , respectively, are observed, consistent with the proposed cyclized intermediates. Similarly, the corresponding cyclic alkyl proton at the 1'-position in 6 (Figure 4) is significantly downfield at 5.58–5.51 ppm in DMSO- $d_6$ .<sup>21</sup> Similar compounds, such as 2,3-dihydro[1,3]-thiazolo[2,3-b][1,3]benzothiazol-4-ium bromide,<sup>24</sup> also show downfield cyclic alkyl protons at around 5 ppm in DMSO- $d_6$ .

Finally, in a series of preliminary C–C coupling experiments, we found that  $(\pm)$ -2a was a competent precatalyst for several reactions, including a Suzuki–Miyaura coupling, a Mizoroki–Heck reaction, and a dehydrogenative cross-coupling, when it was tested in air with conditions from the literature without further optimization (see Scheme S3 in the Supporting Information).



**Figure 5.** Time course of the reaction between **1a** and  $Pd(TFA)_2$  to yield **2a**, taken in  $CDCl_3$  with important new peaks highlighted. Full <sup>1</sup>H NMR spectra, precipitate analysis (DMSO- $d_6$ ), and the time course experiment with **1c** are available in the Supporting Information.

#### CONCLUSIONS

We have herein identified a novel rearrangement leading to tetrahydrothiophene-functionalized NSHC palladium(II) complexes. Using X-ray, NMR, and HRMS data, the identities of these [3.2.1]palladabicyclic products were confirmed. Through the synthesis of analogous complexes as well as the monitoring of the reaction progress of the formation of  $(\pm)$ -2a and  $(\pm)$ -2c, two plausible and closely related mechanisms can be proposed. Understanding this rearrangement process may bolster use of the benzo[d]thiazole directing group in catalytic alkene functionalization reactions. Additionally,  $(\pm)$ -2a can successfully catalyze three C-C coupling reactions, suggesting that complexes containing bidentate NSHC ligands can be developed and explored further as a new class of catalysts.

#### EXPERIMENTAL SECTION

**General Information.** Except where otherwise stated, all materials were used as received from commercial sources without further purification. All reactants, reagents, and solvents unless otherwise mentioned were purchased from Aldrich, Alfa Aesar, Oakwood, and Combi-Blocks and used without further drying or purification. All reactions were run in an atmosphere of air. NMR spectra were recorded on an AV-600 machine. Spectra were internally referenced to SiMe<sub>4</sub>, the solvent signal, or an internal standard. The following abbreviations (or combinations thereof) were used to explain multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet. High-resolution mass spectra (HRMS) for new compounds were obtained with a Waters I-Class LC with diode array and G2-XS time-of-flight (TOF) mass spectrometer or with an Agilent LC/MSD TOF mass spectrometer.

Synthesis of Complexes ( $\pm$ )-2a–4. In a 1 dram (4 mL) vial equipped with a magnetic stir bar were placed the corresponding benzo[d]thiazole-containing material (0.2 mmol, 2 equiv) and the palladium-containing material (PdX<sub>2</sub>) (0.1 mmol, 1 equiv). To this mixture was added 1,2-DCE (1 mL, 0.1 M), and the vial was capped. The reaction mixture was stirred at 500 rpm at 45 °C for 12 h. Without cooling to room temperature, the crude solution was transferred into a new 1 dram (4 mL) vial. This uncapped vial with the crude mixture was placed inside a scintillation vial (20 mL). Diethyl ether (2 mL) was placed in the scintillation vial without any

addition into the 1 dram vial containing the crude material in preparation for vapor diffusion. The scintillation vial was capped and allowed to sit undisturbed for 72 h. The 1 dram vial was then removed from the scintillation vial and the solvent carefully removed with a pipet, leaving crystals, which were washed with additional diethyl ether ( $3 \times 3$  mL). The remaining diethyl ether was then removed *in vacuo* to provide the pure product.

*Complex* (±)-**2a**. The title compound was prepared with 2-(but-3en-1-ylthio)benzo[*d*]thiazole (**1a**) and Pd(TFA)<sub>2</sub> on a 0.300 mmol scale. Purification afforded (±)-**2a** as a yellow crystal (137 mg, 41%). <sup>1</sup>H NMR (600 MHz, acetone-*d*<sub>6</sub>):  $\delta$  8.33 (d, *J* = 8.6 Hz, 1H), 8.25 (dd, *J* = 8.1, 1.2 Hz, 1H), 7.79 (ddd, *J* = 8.5, 7.2, 1.2 Hz, 1H), 7.72– 7.67 (m, 1H), 6.65 (t, *J* = 5.6 Hz, 1H), 4.14 (tt, *J* = 8.4, 5.0 Hz, 1H), 3.81 (d, *J* = 13.9 Hz, 1H), 3.51–3.42 (m, 2H), 3.12–3.03 (m, 1H), 2.89–2.84 (m, 1H). <sup>13</sup>C NMR (151 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  178.37, 142.99, 132.90, 127.91, 126.74, 123.18, 115.44, 66.23, 45.11, 41.96, 38.51, 34.19. HRMS: calcd for C<sub>13</sub>H<sub>11</sub>F<sub>3</sub>NO<sub>2</sub><sup>106</sup>PdS<sub>2</sub><sup>+</sup> [M/2 – TFA]<sup>+</sup>, 439.9218; found, 439.9219. Single crystals suitable for X-ray diffraction were obtained directly from the procedure described above (CCDC 2057872).<sup>28</sup>

Complex 2b. The title compound was prepared with 2-(pent-4-en-2-ylthio)benzo[d]thiazole (1b) and Pd(TFA)<sub>2</sub>. Purification afforded **2b** as a yellow crystal (40 mg, 35%) with dr = 1.4:1 when (S)-2-(pent-4-en-2-ylthio)benzo[d]thiazole was used and dr = 1:3.3 when the racemic starting material was used. <sup>1</sup>H NMR (600 MHz, acetone- $d_6$ ):  $\delta$  8.31–8.23 (m, 2H), 7.78 (dtd, I = 8.5, 7.2, 1.2 Hz, 1H), 7.69 (ddt, I= 8.2, 7.2, 1.9 Hz, 1H), 6.65 (t, J = 4.9 Hz, 0.55H), 6.57 (t, J = 6.0 Hz, 0.42H), 4.85 (h, J = 7.2 Hz, 0.59H), 3.93 (dt, J = 9.2, 6.8 Hz, 0.45H), 3.81 (d, J = 14.2 Hz, 1H), 3.66 (dd, J = 14.1, 4.3 Hz, 0.55H), 3.59 (dd, J = 14.0, 4.8 Hz, 0.39H), 3.42-3.34 (m, 0.43H), 3.13-3.06 (m, 0.44H), 2.56 (ddd, J = 14.5, 7.2, 5.7 Hz, 0.50H), 2.40–2.32 (m, 0.45H), 1.97 (d, J = 6.8 Hz, 1.34H), 1.57 (d, J = 7.1 Hz, 1.67H). <sup>13</sup>C NMR (151 MHz, acetone-d<sub>6</sub>): δ 181.37, 144.53, 144.32, 134.62, 128.84, 128.79, 127.66, 127.64, 123.91, 123.86, 115.88, 115.77, 69.20, 66.93, 53.24, 53.13, 44.47, 44.18, 42.96, 40.41, 21.67, 21.27. HRMS: calcd for  $C_{14}H_{13}F_3NO_2^{102}PdS_2^+$  [M/2 – TFA]<sup>+</sup>, 449.9396; found, 449.9388. Single crystals suitable for X-ray diffraction were obtained directly from the procedure described above (CCDC 2057870).<sup>28</sup>

Complex  $(\pm)$ -2c. The title compound was prepared with (E)-2-(hex-3-en-1-ylthio)benzo $\lceil d \rceil$ thiazole ((E)-1c) and Pd(TFA)<sub>2</sub>. Purification afforded  $(\pm)$ -2c as an orange crystal (43 mg, 37%). <sup>1</sup>H NMR (600 MHz, acetone- $d_6$ ):  $\delta$  8.39 (d, J = 8.6 Hz, 1H), 8.25 (dd, J = 8.1, 1.2 Hz, 1H), 7.77 (ddd, J = 8.5, 7.2, 1.2 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H), 6.35 (d, J = 6.4 Hz, 1H), 4.17–4.07 (m, 2H), 3.59 (ddd, J =13.7, 10.7, 5.1 Hz, 1H), 3.17 (ddt, J = 14.8, 10.7, 6.0 Hz, 1H), 2.07-2.11 (m, 2H), 1.86 (ddq, J = 14.5, 9.7, 7.3 Hz, 1H), 1.21 (t, J = 7.3 Hz, 3H). <sup>13</sup>C NMR (151 MHz, acetone-*d*<sub>6</sub>): δ 180.18, 143.14, 132.90, 127.40, 126.27, 122.45, 116.55, 114.60, 114.26, 70.13, 60.09, 43.94, 36.08, 32.22, 29.24, 24.09, 11.12. HRMS: calcd for  $C_{15}H_{15}F_{3}NO_{2}^{-106}PdS_{2}^{+} \ [M/2 \ - \ TFA]^{+}, \ 467.9531; \ found, \ 467.9530.$ Single crystals with a triclinic structure suitable for X-ray diffraction were obtained directly from the procedure described above (CCDC  $2057864)^{28}$  and regrown in a trigonal structure from CDCl<sub>3</sub> (CCDC 2057865).28

*Complex* (±)-2*d*. The title compound was prepared with (*E*)-5chloro-2-(hex-3-en-1-ylthio)benzo[*d*]thiazole (1d) and Pd(TFA)<sub>2</sub>. Purification afforded (±)-2d as an orange crystal (45 mg, 36%). <sup>1</sup>H NMR (600 MHz, acetone-*d*<sub>6</sub>):  $\delta$  8.57–8.49 (m, 1H), 8.27 (d, *J* = 8.6 Hz, 1H), 7.79–7.60 (m, 1H), 6.37 (d, *J* = 6.7 Hz, 1H), 4.22–4.06 (m, 2H), 3.72–3.52 (m, 1H), 3.25–3.08 (m, 1H), 2.94–2.86 (m, 1H), 2.26–2.06 (m, 1H), 1.86 (dddd, *J* = 17.6, 15.0, 8.4, 5.0 Hz, 1H), 1.20 (q, *J* = 8.1 Hz, 3H). <sup>13</sup>C NMR (151 MHz, acetone-*d*<sub>6</sub>):  $\delta$  183.13, 144.60, 133.85, 132.15, 127.03, 124.14, 115.42, 115.13, 115.06, 70.98, 60.60, 44.42, 36.61, 32.65, 24.51, 11.59. HRMS: calcd for C<sub>15</sub>H<sub>14</sub><sup>35</sup>ClF<sub>3</sub>NO<sub>2</sub><sup>104</sup>PdS<sub>2</sub><sup>+</sup> [M/2 – TFA]<sup>+</sup>, 499.9147; found, 499.9134. Single crystals suitable for X-ray diffraction were obtained directly from the procedure described above (CCDC 2057869).<sup>28</sup>

Complex 3a. The title compound was prepared with 2-(but-3-en-1-ylthio)benzo[d]thiazole (1a) and PdBr<sub>2</sub>. Purification afforded 3a as a yellow crystal (33 mg, 46%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  9.16

(d, J = 8.3 Hz, 0.75H), 9.08 (d, J = 8.2 Hz, 0.25H), 7.71 (d, J = 7.9 Hz, 1H), 7.67 (t, J = 8.0 Hz, 1H), 7.44 (t, J = 7.5 Hz, 1H), 5.99 (td, J = 16.9, 6.9 Hz, 1H), 5.40–5.11 (m, 2H), 3.50–3.38 (m, 2H), 2.86–2.70 (m, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  174.35, 173.72, 150.39, 134.93, 134.86, 131.22, 131.11, 127.78, 125.72, 122.72, 122.62, 121.35, 121.26, 118.23, 118.06, 35.50, 35.45, 33.08, 32.96, 29.86. HRMS: calcd for  $C_{22}H_{24}^{-79}BrN_2^{106}PdS_4^+$  [M – Br + 2H]<sup>+</sup>, 628.9041; found, 628.9022. Single crystals suitable for X-ray diffraction were obtained directly from the procedure described above (CCDC 2057868).<sup>28</sup>

*Complex* **3b**. The title compound was prepared with 2-(but-3-en-1-ylthio)benzo[*d*]thiazole (**1a**) and PdCl<sub>2</sub>. Crystals were regrown to X-ray quality by slow evaporation of CDCl<sub>3</sub> in an NMR tube. Purification afforded **3b** as a yellow crystal (32 mg, 51%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  9.26 (dt, *J* = 8.3, 0.9 Hz, 0.65H), 9.18 (dt, *J* = 8.2, 0.9 Hz, 0.35H), 7.76–7.71 (m, 1H), 7.68 (ddd, *J* = 8.4, 7.3, 1.2 Hz, 1H), 7.45 (dddd, *J* = 8.2, 7.2, 6.1, 1.1 Hz, 1H), 6.04–5.93 (m, 1H), 5.36–5.18 (m, 2H), 3.48–3.42 (m, 2H), 2.82–2.71 (m, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  173.90, 173.27, 166.39, 152.87, 149.53, 135.26, 134.77, 134.33, 134.25, 130.67, 130.56, 127.32, 125.57, 125.16, 125.13, 123.73, 121.85, 121.70, 121.05, 120.77, 120.69, 120.50, 117.65, 117.48, 116.51, 34.82, 34.80, 32.90, 32.42, 32.30, 29.27. HRMS: calcd for C<sub>22</sub>H<sub>22</sub><sup>35</sup>ClN<sub>2</sub><sup>106</sup>PdS<sub>4</sub><sup>+</sup> [M – Cl]<sup>+</sup>, 582.9386; found, 582.9402. Single crystals suitable for X-ray diffraction were obtained directly from the procedure described above (CCDC 2051103).<sup>28</sup>

*Complex* **4**. The title compound was prepared with 2-((2-methylbutyl)thio)benzo[*d*]thiazole (1e) and Pd(TFA)<sub>2</sub>. Purification afforded 4 as an orange crystal (23 mg, 40%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  9.30 (dd, *J* = 11.2, 8.4 Hz, 1H), 7.70 (dq, *J* = 12.6, 8.8 Hz, 2H), 7.44 (t, *J* = 7.7 Hz, 1H), 3.37 (ddd, *J* = 13.1, 7.8, 5.9 Hz, 1H), 3.25–3.16 (m, 1H), 2.00 (qd, *J* = 13.7, 6.7 Hz, 1H), 1.68 (dtt, *J* = 13.0, 10.1, 6.3 Hz, 1H), 1.44 (dpd, *J* = 14.8, 7.4, 3.0 Hz, 1H), 1.19 (dd, *J* = 6.7, 4.2 Hz, 3H), 1.01 (q, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  176.59, 176.41, 149.81, 149.72, 130.54, 130.42, 128.08, 127.98, 125.81, 125.78, 122.02, 122.00, 121.18, 43.14, 43.04, 35.07, 35.01, 28.98, 28.94, 19.01, 11.37. HRMS: calcd for C<sub>26</sub>H<sub>30</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub><sup>106</sup>PdS<sub>4</sub><sup>+</sup> [M - TFA]<sup>+</sup>, 693.0177; found, 693.0168. Single crystals suitable for X-ray diffraction were obtained directly from the procedure described above (CCDC 2057871).<sup>28</sup>

Synthetic Procedure for Complex 5. In a 1 dram (4 mL) vial equipped with a magnetic stir bar were placed 2-(but-3-en-1ylthio)benzo[d]thiazole (1a) (0.10 mmol, 2 equiv) and silver triflate (AgOTf) (0.05 mmol, 1 equiv). To this mixture was added 1,2-DCE (0.5 mL, 0.1 M), and the vial was capped. The reaction mixture was stirred at 500 rpm at 45 °C for 12 h. Without cooling to room temperature, the crude solution was transferred into a new 1 dram (4 mL) vial. This uncapped vial with the crude mixture was placed inside a scintillation vial (20 mL). Diethyl ether (2 mL) was placed in the scintillation vial without any addition into the 1 dram vial containing the crude material in preparation for vapor diffusion. The scintillation vial was capped and allowed to sit undisturbed for 72 h. The 1 dram vial was then removed from the scintillation vial and the solvent carefully removed with a pipet, leaving crystals, which were washed with additional diethyl ether  $(3 \times 3 \text{ mL})$ . The remaining diethyl ether was then removed in vacuo to provide the pure product 5 as a gray crystal (20 mg, 42%).

<sup>1</sup>H NMR (600 MHz, acetone-*d*<sub>6</sub>): δ 8.12 (dd, *J* = 15.3, 8.2 Hz, 2H), 7.59 (ddd, *J* = 8.3, 5.0, 1.3 Hz, 1H), 7.56–7.49 (m, 1H), 6.24 (ddtd, *J* = 13.4, 8.4, 6.7, 1.8 Hz, 1H), 5.45–5.36 (m, 2H), 3.71 (td, *J* = 6.5, 1.8 Hz, 2H), 2.75 (q, *J* = 6.7 Hz, 2H). <sup>13</sup>C NMR (151 MHz, acetone-*d*<sub>6</sub>): δ 171.79, 152.45, 135.76, 134.98, 128.28, 126.71, 122.93, 122.63, 114.01, 36.68, 33.85. HRMS: calcd for C<sub>11</sub>H<sub>11</sub><sup>107</sup>AgNS<sub>2</sub><sup>+</sup> [M – OTf]<sup>+</sup>, 327.9384; found, 327.9395. Single crystals suitable for X-ray diffraction were obtained directly from the procedure described above (CCDC 2057866).<sup>28</sup>

Synthetic Procedure for 4-(lodomethyl)-3,4-dihydro-2*H*benzo[4,5]thiazolo[2,3-*b*][1,3]thiazin-5-ium Triiodide (6). In a 1 dram (4 mL) vial equipped with a magnetic stir bar were placed 2-(but-3-en-1-ylthio)benzo[*d*]thiazole (1a) (0.5 mmol, 1 equiv) and

samarium(II) iodide (SmI<sub>2</sub>) (0.5 mmol, 0.1 M solution in THF, 1 equiv). To this mixture was added 1,2-DCE (5 mL, 0.1 M), and the vial was capped. The reaction mixture was stirred at 500 rpm at 45 °C for 12 h. Without cooling to room temperature, the crude solution was transferred into a new 1 dram (4 mL) vial. This uncapped vial with the crude mixture was placed inside a scintillation vial (20 mL). Diethyl ether (2 mL) was placed the scintillation vial without any addition into the 1 dram vial containing the crude material. The scintillation vial was capped and allowed to sit undisturbed for 72 h. The 1 dram vial was then removed from the scintillation vial and the solvent carefully removed with a pipet, leaving crystals, which were washed with additional diethyl ether  $(3 \times 3 \text{ mL})$ . The remaining diethyl ether was then removed in vacuo to provide the pure product. While some X-ray-quality crystals were retrievable, the yield of crystals was low (<10%). The reaction was rerun following a literature  $\frac{1}{21}$ procedure.

<sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>): δ 8.32 (dt, *J* = 8.3, 2.0 Hz, 1H), 8.11 (dd, *J* = 8.6, 3.0 Hz, 1H), 7.86–7.78 (m, 1H), 7.71 (td, *J* = 7.7, 3.0 Hz, 1H), 5.54 (dh, *J* = 9.6, 3.1 Hz, 1H), 3.74–3.66 (m, 2H), 3.67–3.54 (m, 2H), 3.01 (dq, *J* = 15.1, 3.3 Hz, 1H), 2.46 (ddd, *J* = 15.5, 10.0, 4.3 Hz, 1H). <sup>13</sup>C NMR (151 MHz, DMSO): δ 175.83, 140.77, 128.69, 127.66, 127.09, 123.98, 114.96, 55.10, 23.25, 23.16, 2.10. Single crystals suitable for X-ray diffraction were obtained directly from the procedure described above (CCDC 2057863).<sup>28</sup>

Synthetic Procedure for [1,1'-Biphenyl]-4-carbaldehyde (7).<sup>25</sup> In a 1 dram (4 mL) vial equipped with a magnetic stir bar were placed 4-bromobenzaldehyde (0.3 mmol, 1 equiv), phenylboronic acid (0.36 mmol, 1.2 equiv), potassium carbonate (K2CO3) (1.0 mmol, 2 equiv), and (±)-2a (0.0015 mmol, 0.5 mol %). To this mixture was added a 1/1 mixture of H<sub>2</sub>O and DMF (3 mL, 0.1 M). The vial was capped, placed on a preheated hot plate at 100 °C, and stirred at 500 rpm for 12 h. The reaction mixture was removed from the stir plate and cooled. The contents of the vial were transferred to a separation vial with subsequent washing of H<sub>2</sub>O and EtOAc. Additional  $H_2O$  (50 mL) was placed in the separation vial, and the desired material was extracted with EtOAc ( $3 \times 50$  mL) and dried with Na2SO4. After the solvent was removed in vacuo, the crude residue was purified by SiO<sub>2</sub> gel column chromatography (5% EtOAc/95% hexanes). Purification afforded 7 as a white solid (90 mg, >95%).

<sup>1</sup>H NMR (600 MHz,  $CDCl_3$ ):  $\delta$  10.06 (s, 1H), 7.95 (d, J = 8.2 Hz, 2H), 7.75 (d, J = 8.2 Hz, 2H), 7.64 (d, J = 8.1 Hz, 2H), 7.49 (t, J = 7.8 Hz, 2H), 7.42 (t, J = 7.5 Hz, 1H). <sup>13</sup>C NMR (151 MHz,  $CDCl_3$ ):  $\delta$  192.00, 147.24, 139.76, 135.27, 130.35, 129.10, 128.56, 127.75, 127.44.

Synthetic Procedure for (E)-4-(4-Methylstyryl)benzaldehyde (8).<sup>26</sup> In a 1 dram (4 mL) vial equipped with a magnetic stir bar were placed the corresponding 4-bromobenzaldehyde (0.3 mmol, 1 equiv), 1-methyl-4-vinylbenzene (0.36 mmol, 1.2 equiv), potassium carbonate (K2CO3) (1.0 mmol, 2 equiv), and  $(\pm)$ -2a (0.0015 mmol, 0.5 mol %). To this mixture was added a 1/1mixture of H<sub>2</sub>O and DMF (3 mL, 0.1 M). The vial was capped, placed on a preheated hot plate at 100 °C, and stirred at 500 rpm for 12 h. The reaction mixture was removed from the stir plate and cooled. The contents of the vial were transferred to a separation vial with subsequent washing of  $H_2O$  and EtOAc. Additional  $H_2O$  (50 mL) was placed in the separation vial, and the desired material was extracted with EtOAc ( $3 \times 50$  mL) and dried with Na<sub>2</sub>SO<sub>4</sub>. After the solvent was removed in vacuo, the crude residue was purified by SiO<sub>2</sub> gel column chromatography (5% EtOAc/95% hexanes). Purification afforded 8 as a yellow solid (45 mg, 67%).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  9.99 (s, 1H), 7.86 (d, *J* = 8.0 Hz, 2H), 7.64 (d, *J* = 8.1 Hz, 2H), 7.45 (d, *J* = 7.8 Hz, 2H), 7.27–7.19 (m, 3H), 7.10 (d, *J* = 16.2 Hz, 1H), 2.38 (s, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  191.79, 143.83, 138.77, 135.31, 133.93, 132.33, 130.40, 129.71, 126.99, 126.92, 126.47, 21.49.

Synthetic Procedure for 5-(Benzo[d]oxazol-2-yl)thiophene-2-carbaldehyde (9).<sup>27</sup> In a 1 dram (4 mL) vial equipped with a magnetic stir bar were placed benzo[d]oxazole (0.1 mmol, 1 equiv), thiophene-2-carbaldehyde (0.2 mmol, 2 equiv), silver acetate (AgOAc) (0.2 mmol, 2 equiv), and ( $\pm$ )-2a (0.05 mmol, 5 mol %). To this mixture was added a 1/1 mixtue of H<sub>2</sub>O and DMSO (1 mL, 0.1 M). The vial was capped, placed on a preheated hot plate at 110 °C, and stirred at 500 rpm for 12 h. The reaction mixture was removed from the stir plate and cooled. The contents of the vial were transferred to a separation vial with subsequent washing of H<sub>2</sub>O and EtOAc. Additional H<sub>2</sub>O (50 mL) was placed the separation vial, and the desired material was extracted with EtOAc (3 × 50 mL) and dried with Na<sub>2</sub>SO<sub>4</sub>. After the solvent was removed *in vacuo*, the crude residue was purified by SiO<sub>2</sub> gel column chromatography (5% EtOAc/95% hexanes). Purification afforded **9** as a yellow solid (14 mg, 61%).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  10.00 (d, J = 2.1 Hz, 1H), 7.97 (dd, J = 3.9, 2.1 Hz, 1H), 7.82 (dd, J = 4.0, 2.1 Hz, 1H), 7.79 (dt, J = 8.5, 1.7 Hz, 1H), 7.63–7.57 (m, 1H), 7.40 (pt, J = 7.4, 1.7 Hz, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  183.00, 157.81, 150.82, 146.39, 141.97, 137.78, 136.25, 130.04, 126.37, 125.41, 120.61, 110.93.

#### ASSOCIATED CONTENT

#### **Supporting Information**

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.organomet.1c00041.

Experimental details, spectral data, NMR spectra, X-ray crystallographic data, and computational details (PDF) NMR data (ZIP)

#### **Accession Codes**

CCDC 2051103 and 2057863–2057872 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data\_request/ cif, or by emailing data\_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

#### AUTHOR INFORMATION

#### **Corresponding Author**

Keary M. Engle – Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037, United States; orcid.org/0000-0003-2767-6556; Email: Keary@ Scripps.edu

#### Authors

- Andrew M. Romine Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037, United States; orcid.org/0000-0002-6703-2926
- Matthew J. Demer Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037, United States; orcid.org/0000-0003-2720-1219
- Milan Gembicky Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093, United States
- Arnold L. Rheingold Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093, United States; o orcid.org/0000-0003-4472-8127

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.organomet.1c00041

#### **Author Contributions**

The manuscript was written through contributions of all authors, and all authors have given approval to the final version of the manuscript.

#### Notes

The authors declare no competing financial interest.

#### ACKNOWLEDGMENTS

This work was financially supported by the National Institutes of Health (5R35GM125052). We further acknowledge the National Science Foundation for a Graduate Research Fellowship (NSF/DGE-1842471, A.M.R.) and the Hearst Foundations for supporting a high school internship (M.J.D.). We thank Dr. Jason S. Chen and staff at the Scripps Research Automated Synthesis Facility for assistance with analytical work as well as the Baran group for use of their HRMS. Furthermore, we thank Lea Dettling (Freie Universität Berlin) for scientific discussions and Lucas J. Oxtoby and Tanner C. Jankins for helpful suggestions in the preparation of this manuscript.

#### ABBREVIATIONS

NHC, N-heterocyclic carbene; CAAC, cyclic (alkyl)- and (aryl)(amino)carbenes; aNHC, abnormal N-heterocyclic carbene; NXHC, N,X-heterocyclic carbene (X = O, P, S, etc.); Pd(TFA)<sub>2</sub>, palladium(II) trifluoroacetate; 1,2-DCE, 1,2-dichloroethane; HRMS, high-resolution mass spectrometry; TFA, trifluoroacetate; AgOTf, silver(I) trifluoromethansulfonate; AgOAc, silver(I) acetate

#### REFERENCES

(1) For selected early reports, see: (a) Arduengo, A. J., III; Harlow, R. L.; Kline, M. A Stable Crystalline Carbene. J. Am. Chem. Soc. 1991, 113, 361-363. (b) Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Synthesis and Activity of a New Generation of Ruthenium-Based Olefin Metathesis Catalysts Coordinated with 1,3-Dimesityl-4,5dihydroimidazol-2-ylidene Ligands. Org. Lett. 1999, 1, 953-956. (c) Hahn, F. E.; Wittenbecher, L.; Boese, R.; Bläser, D. N,N'-Bis(2,2dimethylpropyl)benzimidazolin-2-ylidene: A Stable Nucleophilic Carbene Derived from Benzimidazole. Chem. - Eur. J. 1999, 5, 1931-1935. For reviews, see (d) N-Heterocyclic Carbenes in Transition Metal Catalysis, 1st ed.; Glorius, F., Ed.; Springer-Verlag: Berlin Heidelberg, 2007. DOI: 10.1007/978-3-540-36930-1. (e) Herrmann, W. A. N-Heterocyclic Carbenes: A New Concept in Organometallic Catalysis. Angew. Chem., Int. Ed. 2002, 41, 1290-1309. (f) Hahn, F. E. Heterocyclic Carbenes. Angew. Chem., Int. Ed. 2006, 45, 1348-1352. (g) Cazin, C. S. J. N-Heterocyclic Carbenes. Dalton Trans. 2013, 42, 7254-7254.

(2) For reviews, see: (a) Arduengo, A. J., III. Looking for Stable Carbenes: The Difficulty in Starting Anew. Acc. Chem. Res. 1999, 32, 913-921. (b) Nelson, D. J.; Nolan, S. P. Quantifying and Understanding the Electronic Properties of N-Heterocyclic Carbenes. Chem. Soc. Rev. 2013, 42, 6723-6753. (c) Fliedel, C.; Schnee, G.; Avilés, T.; Dagorne, S. Group 13 Metal (Al, Ga, In, Tl) Complexes Supported by Heteroatom-Bonded Carbene Ligands. Coord. Chem. Rev. 2014, 275, 63-86. (d) Peris, E. Smart N-Heterocyclic Carbene Ligands in Catalysis. Chem. Rev. 2018, 118, 9988-10031. (e) Nesterov, V.; Reiter, D.; Bag, P.; Frisch, P.; Holzner, R.; Porzelt, A.; Inoue, S. NHCs in Main Group Chemistry. Chem. Rev. 2018, 118, 9678-9842. (f) Vivancos, Á.; Segarra, C.; Albrecht, M. Mesoionic and Related Less Heteroatom-Stabilized N-Heterocyclic Carbene Complexes: Synthesis, Catalysis, and Other Applications. Chem. Rev. 2018, 118, 9493-9586. (g) Danopoulos, A. A.; Simler, T.; Braunstein, P. N-Heterocyclic Carbene Complexes of Copper, Nickel, and Cobalt. Chem. Rev. 2019, 119, 3730-3961. (h) Doddi, A.; Peters, M.; Tamm, M. N-Heterocyclic Carbene Adducts of Main Group Elements and Their Use as Ligands in Transition Metal Chemistry. Chem. Rev. 2019, 119, 6994-7112. (i) Zhao, Q.; Meng, G.; Nolan, S. P.; Szostak, M. N-Heterocyclic Carbene Complexes in C-H Activation Reactions. Chem. Rev. 2020, 120, 1981-2048. (j) Liang, Q.; Song, D. Iron N-Heterocyclic Carbene Complexes in Homogeneous Catalysis. Chem. Soc. Rev. 2020, 49, 1209-1232.

(3) For reviews, see: (a) Melaimi, M.; Soleilhavoup, M.; Bertrand, G. Stable Cyclic Carbenes and Related Species beyond Diaminocarbenes. Angew. Chem., Int. Ed. 2010, 498, 8810-8849. (b) Soleilhavoup, M.; Bertrand, G. Cyclic (Alkyl)(Amino)Carbenes (CAACs): Stable Carbenes on the Rise. Acc. Chem. Res. 2015, 48, 256-266. (c) Roy, S.; Mondal, K. C.; Roesky, H. W. Cyclic Alkyl(amino) Carbene Stabilized Complexes with Low Coordinate Metals of Enduring Nature. Acc. Chem. Res. 2016, 49, 357-369. (d) Melaimi, M.; Jazzar, R.; Soleilhavoup, M.; Bertrand, G. Cyclic (Alkyl)(amino)carbenes (CAACs): Recent Developments. Angew. Chem., Int. Ed. 2017, 56, 10046-10068. (e) Paul, U. S. D.; Radius, U. What Wanzlick Did Not Dare To Dream: Cyclic (Alkyl)(amino)carbenes (cAACs) as New Key Players in Transition-Metal Chemistry. Eur. J. Inorg. Chem. 2017, 2017, 3362-3375. (f) Kundu, S.; Sinhababu, S.; Chandrasekhar, V.; Roesky, H. W. Stable Cyclic (Alkyl)(amino)carbene (cAAC) Radicals with Main Group Substituents. Chem. Sci. 2019, 10, 4727-4741. (g) Jazzar, R.; Soleilhavoup, M.; Bertrand, G. Cyclic (Alkyl)- and (Aryl)(amino)carbene Coinage Metal Complexes and Their Applications. Chem. Rev. 2020, 120, 4141-4168.

(4) For a review, see: Sau, S. C.; Hota, P. K.; Mandal, S. K.; Soleilhavoup, M.; Bertrand, G. Stable Abnormal N-Heterocyclic Carbenes and Their Applications. *Chem. Soc. Rev.* **2020**, *49*, 1233–1252.

(5) For a review, see: Eicher, T.; Hauptmann, S.; Speicher, A. *The Chemistry of Heterocycles: Structures, Reactions, Synthesis, and Applications,* 3rd ed.; Wiley-VCH: Weinheim, Germany, 2013.

(6) For review, see Chien, S. W.; Yen, S. K.; Hor, T. S. A. N,S-Heterocyclic Carbene Complexes. Aust. J. Chem. 2010, 63, 727–741. (7) For a review, see: Schuster, O.; Yang, L.; Raubenheimer, H. G.; Albrecht, M. Beyond Conventional N-Heterocyclic Carbenes: Abnormal, Remote, and Other Classes of NHC Ligands with Reduced Heteroatom Stabilization. Chem. Rev. 2009, 109, 3445– 3478.

(8) Franco, D.; Marchenko, A.; Koidan, G.; Hurieva, A. N.; Kostyuk, A.; Biffis, A. Palladium(II) Complexes with *N*-Phosphanyl-*N*-heterocyclic Carbenes as Catalysts for Intermolecular Alkyne Hydroaminations. *ACS Omega* **2018**, *3*, 17888–17894.

(9) McGuinness, D. S.; Cavell, K. J. Donor-Functionalized Heterocyclic Carbene Complexes of Palladium(II): Efficient Catalysts for C-C Coupling Reactions. *Organometallics* **2000**, *19*, 741–748.

(10) Yang, L.; Guo, Q.; Xiao, Y.; Mao, P. Development of Chelating N-Heterocyclic Carbene Metal Complexes. *Chin. J. Org. Chem.* 2015, 35, 1834–1847.

(11) (a) Wolf, J.; Labande, A.; Daran, J.-C.; Poli, R. Nickel(II), Palladium(II) and Rhodium(I) Complexes of New NHC-Thioether Ligands: Efficient Ketone Hydrosilylation Catalysis by a Cationic Rh Complex. Eur. J. Inorg. Chem. 2007, 2007, 5069-5079. (b) Fliedel, C.; Schnee, G.; Braunstein, P. Versatile Coordination Modes of Novel Hemilabile S-NHC ligands. Dalton Trans. 2009, 2474-2476. (c) Yuan, D.; Huynh, H. V. Syntheses and Characterizations of Thiolato-Functionalized N-Heterocyclic Carbene Pd(II) Complexes with Normal and Mesoionic Binding Modes. Dalton Trans. 2011, 40, 11698-11703. (d) Yuan, D.; Huynh, H. V. Sulfur-Functionalized N-Heterocyclic Carbene Complexes of Pd(II): Syntheses, Structures and Catalytic Activities. Molecules 2012, 17, 2491-2517. (e) Canovese, L.; Visentin, F.; Levi, C.; Santo, C.; Bertolasi, V. Synthesis of Novel Palladium Allyl Complexes Bearing Heteroditopic NHC-S Ligands. Kinetic Study on the Carbene Exchange between Bis-Carbene Palladium Allyl Complexes. J. Organomet. Chem. 2013, 732, 27-39. (f) Liu, Y.; Kean, Z. S.; d'Aquino, A. I.; Manraj, Y. D.; Mendez-Arroyo, J.; Mirkin, C. A. Palladium(II) Weak-Link Approach Complexes Bearing Hemilabile N-Heterocyclic Carbene-Thioether Ligands. Inorg. Chem. 2017, 56, 5902-5910. For a review, see: (g) Bierenstiel, M.; Cross, E. D. Sulfur-Functionalized N-Heterocyclic Carbenes and Their Transition Metal Complexes. Coord. Chem. Rev. 2011, 255, 574-590.

(12) (a) Huynh, H. V.; Yeo, C. H.; Chew, Y. X. Syntheses, Structures, and Catalytic Activities of Hemilabile Thioether-Functionalized NHC Complexes. *Organometallics* **2010**, *29*, 1479–1486. (b) Huynh, H. V.; Chew, Y. X. Synthesis, Structural Characterization and Catalytic Activity of a Palladium(II) Complex Bearing a New Ditopic Thiophene-N-Heterocyclic Carbene Ligand. *Inorg. Chim. Acta* **2010**, *363*, 1979–1983. (c) Fliedel, C.; Braunstein, P. Thioether-Functionalized N-Heterocyclic Carbenes: Mono- and Bis- $(S,C_{NHC})$ Palladium Complexes, Catalytic C–C Coupling, and Characterization of a Unique Ag<sub>4</sub>I<sub>4</sub>( $S,C_{NHC}$ )<sub>2</sub> Planar Cluster. *Organometallics* **2010**, *29*, 5614–5626. (d) Yuan, D.; Huynh, H. V. Dinuclear and Tetranuclear Palladium(II) Complexes of a Thiolato-Functionalized, Benzannulated N-Heterocyclic Carbene Ligand and Their Activities toward Suzuki–Miyaura Coupling. *Organometallics* **2010**, *29*, 6020–6027. For a Ni-catalyzed Sukuki–Miyaura reaction, see: (e) Bernhammer, J. C.; Huynh, H. V. Nickel(II) Benzimidazolin-2-ylidene Complexes with Thioether-Functionalized Side Chains as Catalysts for Suzuki– Miyaura Cross-Coupling. *Organometallics* **2014**, *33*, 5845–5851.

(13) Huynh, H. V.; Yuan, D.; Han, Y. Syntheses and Catalytic Activities of Pseudo-Pincer and CSC Pincer-Type Pd(II) Complexes Derived from Benzannulated N-Heterocyclic Carbenes. *Dalton Trans.* 2009, 7262–7268.

(14) Roseblade, S. J.; Ros, A.; Monge, D.; Alcarazo, M.; Álvarez, E.; Lassaletta, J. M.; Fernández, R. Imidazo[1,5-*a*]pyridin-3-ylidene/ Thioether Mixed C/S Ligands and Complexes Thereof. *Organometallics* **2007**, *26*, 2570–2578.

(15) (a) Yuan, D.; Tang, H.; Xiao, L.; Huynh, H. V. CSC-Pincer versus Pseudo-Pincer Complexes of Palladium(II): A Comparative Study on Complexation and Catalytic Activities of NHC Complexes. Dalton Trans. 2011, 40, 8788–8795. (b) Bernhammer, J. C.; Huynh, H. V. Benzimidazolin-2-ylidene Complexes of Palladium(II) Featuring a Thioether Moiety: Synthesis, Characterization, Molecular Dynamics, and Catalytic Activities. Organometallics 2014, 33, 1266–1275.

(16) Bhaskar, R.; Sharma, A. K.; Singh, A. K. Palladium(II) Complexes of N-Heterocyclic Carbene Amidates Derived from Chalcogenated Acetamide-Functionalized 1*H*-Benzimidazolium Salts: Recyclable Catalyst for Regioselective Arylation of Imidazoles under Aerobic Conditions. *Organometallics* **2018**, *37*, 2669–2681.

(17) Dubey, P.; Gupta, S.; Šingh, A. K. Trinuclear Complexes of Palladium(II) with Chalcogenated N-Heterocyclic Carbenes: Catalysis of Selective Nitrile–Primary Amide Interconversion and Sonogashira Coupling. *Dalton Trans.* **2017**, *46*, 13065–13076.

(18) (a) Huynh, H. V.; Yeo, C. H.; Tan, G. K. Hemilabile Behavior of a Thioether-Functionalized N-Heterocyclic Carbene Ligand. *Chem. Commun.* **2006**, 3833–3835. For reviews, see: (b) Braunstein, P.; Naud, F. Hemilability of Hybrid Ligands and the Coordination Chemistry of Oxazoline-Based Systems. *Angew. Chem., Int. Ed.* **2001**, 40, 680–699. Pearson, R. G. Hard and Soft Acids and Bases—The Evolution of a Chemical Concept. *Coord. Chem. Rev.* **1990**, *100*, 403–425.

(19) Romine, A. M.; Yang, K. S.; Karunananda, M. K.; Chen, J. S.; Engle, K. M. Synthetic and Mechanistic Studies of a Versatile Heteroaryl Thioether Directing Group for Pd(II) Catalysis. *ACS Catal.* **2019**, *9*, 7626–7640.

(20) The relative stereochemistry of the major and minor diastereomers could be assigned by a NOESY analysis of the bulk mixture. From this experiment we confirmed that it was indeed the major and not the minor diastereomer that was identified by single-crystal X-ray analysis.

(21) Yushina, I.; Tarasova, N.; Kim, D.; Sharutin, V.; Bartashevich, E. Noncovalent Bonds, Spectral and Thermal Properties of Substituted Thiazolo[2,3-b][1,3]thiazinium Triiodides. *Crystals* **2019**, *9*, 506.

(22) Cabeza, J. A.; del Río, I.; Sánchez-Vega, M. G.; Suárez, M. Methyl Levamisolium Triflate as a Precursor to a Chiral Bifunctional N-Heterocyclic Carbene-Thiolate Ligand: Palladium(II) Complexes. *Organometallics* **2006**, *25*, 1831–1834.

(23) (a) Pendleton, I. M.; Pérez-Temprano, M. H.; Sanford, M. S.; Zimmerman, P. M. Experimental and Computational Assessment of Reactivity and Mechanism in  $C(sp^3)$ –N Bond-Forming Reductive Elimination from Palladium(IV). J. Am. Chem. Soc. **2016**, 138, 6049– 6060. (b) Park, H.; Verma, P.; Hong, K.; Yu, J.-Q. Controlling Pd(IV) Reductive Elimination Pathways Enables Pd(II)-Catalysed Enantio-selective  $C(sp^3)$ -H Fluorination. *Nat. Chem.* **2018**, *10*, 755-762.

(24) Galliford, C. V.; Voronin, K.; Hesk, D.; Koharski, D.; McNamara, P. Rapid Synthesis of a  ${}^{13}C_6$ -Benzothiazolium Salt from  ${}^{13}C_6$ -Aniline. J. Labelled Compd. Radiopharm. **2011**, 54, 229–232.

(25) Ackermann, L.; Potukuchi, H. K.; Althammer, A.; Born, R.; Mayer, P. Tetra-*ortho*-Substituted Biaryls through Palladium-Catalyzed Suzuki–Miyaura Couplings with a Diaminochlorophosphine Ligand. *Org. Lett.* **2010**, *12*, 1004–1007.

(26) Xu, H.-J.; Zhao, Y.-Q.; Zhou, X.-F. Palladium-Catalyzed Heck Reaction of Aryl Chlorides under Mild Conditions Promoted by Organic Ionic Bases. J. Org. Chem. 2011, 76, 8036–8041.

(27) Xi, P.; Yang, F.; Qin, S.; Zhao, D.; Lan, J.; Gao, G.; Hu, C.; You, J. Palladium(II)-Catalyzed Oxidative C-H/C-H Cross-Coupling of Heteroarenes. J. Am. Chem. Soc. 2010, 132, 1822-1824.

(28) CCDC 2057872 ( $(\pm)$ -2a), 2057870 (2b), 2057864 ( $(\pm)$ -2c, triclinic), 2057865 ( $(\pm)$ -2c, trigonal), 2057869 ( $(\pm)$ -2d), 2057868 (3a), 2051103 (3b), 2057871 (4), 2057866 (5), 2057863 (6), and 2057867 (10) contain supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/ data\_request/cif.